Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Pronota is to Receive Patent on Biomarker for Diagnosing Renal Failure

Published: Friday, June 07, 2013
Last Updated: Friday, June 07, 2013
Bookmark and Share
USPTO has allowed Company’s patent for the use of a blood-based biomarker LG3.

The United States Patent and Trade Office (USPTO) has allowed Pronota’s patent for the use of a blood-based biomarker LG3 in the decision-making process for the treatment of renal dysfunction.

This is a major step forward for Pronota as it reconfirms the patentability of the use of biomarkers.

A decision of the US Supreme Court in Mayo vs. Prometheus in March 2012 had questioned the patentability of the use of biomarkers as patents on diagnostic methods were regarded as claiming a natural law or phenomenon.

The diagnostic industry had been startled by this decision as use of biomarkers was seen as being directed to non-patentable subject-matter.

In close collaboration with the Biotech specialists of US agent Knobbe Martens Olson & Bear LLP (US), the European Patent Attorneys of Boxall IPM (UK) and De Clercq & Partners (Belgium), have now succeeded in reformulating the diagnostic method claims into an allowable format.

These claims provide Pronota with the protection it needs in the US to develop a test which will provide the clinicians with better tools for the evaluation and monitoring of treatment of renal dysfunction.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,200+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pronota’s Risk Stratification Test Breaks New Ground in the Early Detection of Pre-Term Pre-Eclampsia Cases
The test correctly identifies 80% of women at risk for the development of pre-term pre-eclampsia according to a study in collaboration with the SCreening fOr Pregnancy Endpoints (SCOPE) Consortium.
Thursday, July 12, 2012
Pronota Strengthens Management Team
Former VP corporate development Genzyme joins as CBO.
Friday, March 16, 2012
Pronota Awarded Euro 1.87M Grant by Flanders Government
The grant will be used to expand the development of Pronota’s diagnostic and pharmacodiagnostic protein biomarker discovery and validation platform.
Tuesday, July 10, 2007
Scientific News
Unravelling the Role of Key Genes and DNA Methylation in Blood Cell Malignancies
Researchers from the University of Nebraska Medical Center have demonstrated the role of Dnmt3a in safeguarding normal haematopoiesis.
Precision Medicine Guiding Cancer Patients’ Chemotherapy Decision
New study finds doctors use genetic test to measure breast cancer recurrence risk, make tailored treatment recommendations.
Smartphone Laboratory Detects Cancer
Researchers develop low-cost, portable laboratory on a smartphonecapable of analysing multiple samples simultaneously.
Signaling Pathway Could Be Key to Improved Osteoporosis Treatment
Inhibition of SIK2 enzyme both stimulates bone formation and reduces bone breakdown in animal model.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
Genetic Signature Linked to Cancer Prognosis Identified
The results of the analysis of 8,161 tissue samples could in the future help clinicians decide how best to treat a patient as well as aid the development of new targeted treatments.
NIH Commits $6.7 M to Advance DNA, RNA Sequencing Technology
"Can you believe they make DNA sequencers the size of staplers?" asked Meni Wanunu, Ph.D. "Ideas that were crazy twenty years ago are now happening!"
Curcumin Shows Promise as Cancer Treatment
When delivered at the correct circadian phase, curcumin demonstrates sustained toxicity in cancer cells and should be considered for use in patient care.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,200+ scientific videos